Coronaviruses as DNA Wannabes: A New Model for the Regulation of RNA Virus Replication Fidelity

Everett Clinton Smith1,2, Mark R. Denison1,2,3*

1 Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America, 2 The Elizabeth B. Lamb Center for Pediatric Research, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America, 3 Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America

Coronaviruses Contain the Largest Known RNA Genomes

Coronaviruses (CoVs) are positive-sense single-stranded RNA viruses and contain the largest known RNA genomes, ranging from 27 to 32 kilobases in length. CoVs are capable of transspecies movement as evidenced by the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) epidemic in 2002–2003 [1,2]. Additionally, the emergence of Middle East Respiratory Syndrome coronavirus (MERS-CoV) in 2012 demonstrates that CoVs continue to cause severe and lethal human disease [3]. Exactly how CoVs maintain the integrity of their large genomes while generating the population diversity required for emergence and adaptation has been a major question in RNA virology. The discovery of 3’-to-5’ exoribonuclease (ExoN) activity within CoV nonstructural protein 14 (nsp14-ExoN), which is critical for CoV high-fidelity replication, has challenged the long-held paradigm that RNA viruses cannot proofread and raises the possibility of an entirely new model for how RNA viruses regulate replication fidelity. We will summarize: 1) the data supporting proofreading during CoV replication; 2) the possibility of a multi-protein fidelity complex, using E. coli DNA polymerase III as a conceptual framework; and 3) the promise of genetic and therapeutic interference with fidelity regulation as an approach for attenuation and treatment of CoVs.

CoVs Encode a Proofreading 3’-to-5’ Exoribonuclease Distinct from the Viral RNA-Dependent RNA Polymerase

RNA viruses rely primarily on low-fidelity replication by RNA-dependent RNA polymerases (RdRps) to facilitate viral adaptation to complex host environments [4]. Because of the lack of proofreading and repair functions, the average mutation rate of RNA viruses is estimated to be around one mutation per genome per round of replication [5,6]. Much beyond this rate, RNA viruses risk crossing an “error threshold,” or the point at which there are too many deleterious mutations for the viral population to reproduce faithfully [4]. Thus, while allowing for enormous population diversity, the low-fidelity of RdR-mediated replication imposes constraints on both viral genome size and maintenance of genomic integrity, theoretically limiting the size of RNA virus genomes to around ~15 kb [reviewed in [4]]. RNA viruses have evolved several mechanisms to partially circumvent these constraints, including large population sizes, rapid replication cycles, robustness to mutations, recombination, and compact genomes [7,8].

In addition to these mechanisms, CoVs encode several additional RNA-processing functions within their 16 nonstructural proteins (nsp1–16), including a 3’-to-5’ exoribonuclease (nsp14-ExoN; Figure 1). Many of these enzymatic functions likely have facilitated the expansion of the CoV genome beyond the ~15 kb upper limit. CoV nsp14-ExoN contains four conserved DE-D-D acidic residues [Figure 1B; [9]], which are the hallmark of the DEDDh superfamily of DNA and RNA exonucleases. Many of these DEDDh exonucleases are involved in proofreading [10]. Alanine substitutions at the CoV DE-D-D residues significantly reduces or abolishes the nucleolytic activity of nsp14-ExoN in vitro [9] and results in CoVs with up to 20-fold reduced fidelity (increased mutation rate) in vitro [11,12] and in vivo [13]. A recent biochemical study demonstrated that nsp14-ExoN is capable of removing single 3’ mismatched nucleotides and that this activity is stimulated by the non-enzymatic protein nsp10 [14]. Thus, all biochemical and genetic studies indicate that CoV nsp14-ExoN performs a proofreading function during CoV replication.

Is nsp14-ExoN the Proofreading Component of a Multi-Subunit Polymerase Complex Containing nsp10 and nsp12-RdRp?

The identification of a proofreading exoribonuclease distinct from the CoV RNA-dependent RNA polymerase (nsp12-RdRp) suggests that CoVs might use a multi-protein complex for RNA synthesis and regulation of fidelity. A possible analogy would be the E. coli DNA polymerase III (pol III) core (τξδ), which contains a polymerase (τ subunit), a DEDDh exonuclease (δ subunit), and an exonuclease stimulatory protein (θ subunit) [15]. Is there evidence to support or to even suggest the possibility that CoVs contain a DNA pol III-like multi-subunit polymerase complex? Several lines of evidence support the hypothesis that regulation of CoV fidelity involves, at minimum, three nsp: nsp12-RdRp, nsp14-ExoN, and nsp10 (Figure 1C). The presence of nsp12-RdRp would be critical as nsp14-ExoN has not been demonstrated to possess polymerase activity, and thus error recognition, removal, and repair would require interactions between nsp14-ExoN and nsp12-RdRp on elongating RNA. Several studies with...
poliovirus, chikungunya virus, and Coxsackievirus have demonstrated that point mutations within the viral RdRp can decrease or increase fidelity [16–19]. While the fidelity of nucleoside triphosphate (NTP) incorporation for nsp12-RdRp has not been determined, CoV nsp12-RdRp would provide essential polymerase activity and likely function to regulate fidelity primarily through NTP discrimination.

The CoV nsp10 is a 130 amino acid protein with no identified enzymatic function that has been demonstrated to bind and enhance nsp14-ExoN activity in vitro by up to 35-fold [14]. While the fidelity of nucleoside triphosphate (NTP) incorporation for nsp12-RdRp has not been determined, CoV nsp12-RdRp would provide essential polymerase activity and likely function to regulate fidelity primarily through NTP discrimination.

The CoV nsp10 is a ~130 amino acid protein with no identified enzymatic function that has been demonstrated to bind and enhance nsp14-ExoN activity in vitro by up to 35-fold [14]. While the fidelity of nucleoside triphosphate (NTP) incorporation for nsp12-RdRp has not been determined, CoV nsp12-RdRp would provide essential polymerase activity and likely function to regulate fidelity primarily through NTP discrimination.

The CoV nsp10 is a ~130 amino acid protein with no identified enzymatic function that has been demonstrated to bind and enhance nsp14-ExoN activity in vitro by up to 35-fold [14]. While the fidelity of nucleoside triphosphate (NTP) incorporation for nsp12-RdRp has not been determined, CoV nsp12-RdRp would provide essential polymerase activity and likely function to regulate fidelity primarily through NTP discrimination.

The CoV nsp10 is a ~130 amino acid protein with no identified enzymatic function that has been demonstrated to bind and enhance nsp14-ExoN activity in vitro by up to 35-fold [14]. While the fidelity of nucleoside triphosphate (NTP) incorporation for nsp12-RdRp has not been determined, CoV nsp12-RdRp would provide essential polymerase activity and likely function to regulate fidelity primarily through NTP discrimination.

The CoV nsp10 is a ~130 amino acid protein with no identified enzymatic function that has been demonstrated to bind and enhance nsp14-ExoN activity in vitro by up to 35-fold [14]. While the fidelity of nucleoside triphosphate (NTP) incorporation for nsp12-RdRp has not been determined, CoV nsp12-RdRp would provide essential polymerase activity and likely function to regulate fidelity primarily through NTP discrimination.

The CoV nsp10 is a ~130 amino acid protein with no identified enzymatic function that has been demonstrated to bind and enhance nsp14-ExoN activity in vitro by up to 35-fold [14]. While the fidelity of nucleoside triphosphate (NTP) incorporation for nsp12-RdRp has not been determined, CoV nsp12-RdRp would provide essential polymerase activity and likely function to regulate fidelity primarily through NTP discrimination.

The CoV nsp10 is a ~130 amino acid protein with no identified enzymatic function that has been demonstrated to bind and enhance nsp14-ExoN activity in vitro by up to 35-fold [14]. While the fidelity of nucleoside triphosphate (NTP) incorporation for nsp12-RdRp has not been determined, CoV nsp12-RdRp would provide essential polymerase activity and likely function to regulate fidelity primarily through NTP discrimination.

The CoV nsp10 is a ~130 amino acid protein with no identified enzymatic function that has been demonstrated to bind and enhance nsp14-ExoN activity in vitro by up to 35-fold [14]. While the fidelity of nucleoside triphosphate (NTP) incorporation for nsp12-RdRp has not been determined, CoV nsp12-RdRp would provide essential polymerase activity and likely function to regulate fidelity primarily through NTP discrimination.

The CoV nsp10 is a ~130 amino acid protein with no identified enzymatic function that has been demonstrated to bind and enhance nsp14-ExoN activity in vitro by up to 35-fold [14]. While the fidelity of nucleoside triphosphate (NTP) incorporation for nsp12-RdRp has not been determined, CoV nsp12-RdRp would provide essential polymerase activity and likely function to regulate fidelity primarily through NTP discrimination.
capacity of nucleic acid to be bound by multiple nsp9 dimers strongly suggests that nsp9 could function as an SSB-like molecule, thus protecting the CoV genome from degradation during replication (Figure 1C). NTPase and helicase activity have been identified within nsp13 of human coronavirus 229E [26,27]. Because dsRNA is likely an abundant replicative intermediate, nsp13 could function ahead of the polymerase complex and unwind the dsRNA, which would then be subsequently bound by nsp9. More recent work has shown that SARS-CoV nsp8 has non-canonical RdRp activity and likely functions as a primase [28]. Additionally, two distinct folds of nsp8, named I and II, participate in a hexadecameric nsp7-nsp8 supercomplex capable of primer extension and binding RNA, likely due to the presence of a central channel lined with positively charged amino acids (Figure 1C) [29,30]. Combined, these studies suggest that the nsp7-nsp8 supercomplex could be analogous to the β sliding clamp within the pol III holoenzyme, which increases both the processivity and speed of the α subunit [15].

Is Fidelity Regulation a Target for CoV Inhibitors?

Ribavirin (RBV) and 5-fluorouracil (5-FU) have been shown to be mutagenic for many RNA viruses (reviewed in [31]). Nucleoside analogs, including both mutagens and chain terminators, have been tested or are used to treat many RNA and DNA viruses, including herpesviruses, HIV, hepatitis C virus, and hepatitis B virus. However, in vitro and in vivo studies demonstrate the limited antiviral activity and variable effectiveness of RBV against SARS-CoV infection [32,33]. Our recent study shows that nsp14-ExoN is responsible for CoV resistance to RNA mutagens, SARS-CoV and murine hepatitis virus (MHV) lacking ExoN activity (ExoN−) demonstrate 160- to 300-fold increased sensitivity to 5-FU [34]. While 5-FU treatment significantly increases the number of mutations present within both wild-type (ExoN+) and ExoN− viruses, almost 4,000 mutations were present in the ExoN− population following a single round of replication (Figure 2). This suggests that small-molecule inhibitors of ExoN could reproduce this genetic defect, and render CoVs vulnerable to treatment with RNA mutagens and obligate or non-obligate chain-terminating nucleoside analogs. The complete conservation of the ExoN− genotype and phenotype in CoVs studied to date [11–13], and the lack of redundancy or complementation of ExoN activity, further suggests that ExoN inhibition is a broadly applicable approach to therapeutically target CoVs. Furthermore, ExoN− viruses are highly attenuated in vivo, suggesting that small-molecule inhibition of ExoN activity would also significantly impact virus infection and virulence [13]. Finally, the probability that fidelity is regulated by a multi-protein complex involving nsp12-RdRp, nsp14-ExoN, and nsp10 suggests that interference with fidelity could be achieved through the disruption of multiple enzymatic activities and/or protein-protein interactions. The opportunity to disrupt the process of CoV fidelity regulation through the simultaneous targeting of multiple proteins, instead of a single protein or enzymatic function, has the potential for broad applicability and for potentially thwarting the emergence of resistance, particularly in combination with mutagens or other nucleoside analogs.

Summary

Coronaviruses encode a proofreading exoribonuclease that is responsible for genome expansion, increased robustness to mutations, and resistance to mis-incorporations during RNA synthesis, as well as being required for virulence. The stability of the ExoN− genotype and phenotype provides a powerful model for the study of additional CoV fidelity determinants and of the effects of altered fidelity on virus replication, fitness, host-species range, and response to environmental changes. Experiments testing the proposed multi-subunit fidelity complex will yield exciting new insights into how CoVs ignore the RNA virus
playbook and instead seem to play by their own rules while dancing on the edge of genetic disaster.

References

1. Drosten C, Gumbiner S, Preiser W, van der Werf S, Brodt HR, et al. (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348: 1967–1976.
2. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, et al. (2003) A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348: 1934–1946.
3. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367: 1014–1020.
4. Domingo E, Sheldon J, Perales C (2012) Viral quasispecies evolution. Microbiol Mol Biol Rev 76: 159–216.
5. Malpica JM, Fraile A, Moreno I, Obst CL, Drake JW, et al. (2002) The rate and character of spontaneous mutation in an RNA virus. Genetics 162: 1305–1311.
6. Drake JW, Holland JJ (1999) Mutation rates among RNA viruses. Proc Natl Acad Sci U S A 96: 13910–13913.
7. Graci JD, Naden PF, Galarraga JE, Castro C, Vignuzzi M, et al. (2012) Mutational robustness of an RNA virus influences sensitivity to lethal mutagenesis. J Virol 86: 2869–2873.
8. Minkaia E, Hertzig T, Gorbalenya AE, Campanacci V, Cambillau C, et al. (2007) National migration of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. PLoS Pathog 3: e1000086. doi:10.1371/journal.ppat.1000086.
9. Eckerle LD, Becker MM, Halpin RA, Li K, Venter E, et al. (2010) Infielty of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. PLoS Pathog 6: e1000896. doi:10.1371/journal.ppat.1000896.
10. Eckerle LD, Lu X, Sperry SM, Choi L, Denison MR (2007) High fidelity of murine hepatitis virus replication is decreased in nsp14 exonuclease mutants. J Virol 81: 12135–12144.
11. Graham RL, Becker MM, Eckerle LD, Bolles M, Denison MR, et al. (2012) A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat Med 18: 1820–1826.
12. Bouvet M, Imbert I, Subassi L, Ghias L, Canard B, et al. (2012) RNA 3′-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exonuclease complex. Proc Natl Acad Sci U S A 109: 9372–9377.
13. Johnson A, O’Donnell M (2005) Cellular DNA repliases: components and dynamics at the replication fork. Annu Rev Biochem 74: 283–315.
14. Naden PF, Beaucourt S, Campagnola G, Borderia AV, Saznov-Kamos M, et al. (2012) Coxackievirus B3 mutator strains are attenuated in vivo. Proc Natl Acad Sci U S A 109: E2294–2303.
15. Coffey LL, Beehray Y, Borderia AV, Blanc H, Vignuzzi M (2011) Arborivirus high fidelity variant loses fitness in mosquitoes and mice. Proc Natl Acad Sci U S A 108: 16030–16035.
16. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R (2006) Quasispecies diversity drives pathogenesis through cooperative interactions in a viral population. Nature 439: 344–348.

Acknowledgments

Space limitations did not allow for citing the important work of all of our colleagues, for which we apologize.

19. Pfister JK, Kirkegaard K (2003) A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci U S A 100: 7289–7294.
20. Donaldson EF, Sims AC, Graham RL, Denison MR, Baric RS (2007) Murine hepatitis virus replicase protein nsp10 is a critical regulator of viral RNA synthesis. J Virol 81: 6356–6366.
21. Donaldson EF, Graham RL, Sims AC, Denison MR, Baric RS (2007) Analysis of murine hepatitis virus strain A39 temperature-sensitive mutant TS-LA6 suggests that nsp10 plays a critical role in polyprotein processing. J Virol 81: 7086–7090.
22. Joseph JS, Saikatendu KS, Subramanian V, Neuman BW, Breslou A, et al. (2006) Crystal structure of nonstructural protein 10 from the severe acute respiratory syndrome coronavirus reveals a novel fold with two zinc-binding motifs. J Virol 80: 7894–7901.
23. Studwell-Vaughan PS, O’Donnell M (1993) DNA polymerase III accessory proteins. V. Theta encoded by holE. J Biol Chem 268: 11785–11791.
24. Tait-Benz SA, Schaeper RM (2004) The theta subunit of Escherichia coli DNA polymerase III, a role in stabilizing the epsilon proofreading subunit. J Bacteriol 186: 2774–2780.
25. Egloff MP, Ferron F, Campanacci V, Longhi S, Rancurel C, et al. (2004) The severe acute respiratory syndrome coronavirus replicative protein nsp9 is a single-stranded RNA-binding subunit unique in the RNA virus world. Proc Natl Acad Sci U S A 101: 3792–3796.
26. Seybert A, Hegyi A, Siddell SG, Ziebuhr J (2000) The human coronavirus strain 229E superfamily 1 helicase has RNA and DNA duplex-unwinding activities with 5′-to-3′ polarity. RNA 6: 1056–1068.
27. Seybert A, Ziebuhr J (2001) Guanosine triphosphatase activity of the human coronavirus helicase. Adv Exp Med Biol 494: 255–260.
28. Imbert I, Guillemeot JC, Bouchir JM, Buissett G, Coutard B, et al. (2006) A second, non-canonical RNA-dependent RNA polymerase in SARS coronavirus. EMBO J 25: 4933–4942.
29. Zhai Y, Sun F, Li X, Pang H, Xu X, et al. (2005) Insights into SARS-CoV transcription and replication from the structure of the nsp7-nsp8 hexadecamer. Nat Struct Mol Biol 12: 980–986.
30. te Velthuis AJ, van den Worm SH, Snijder EJ (2012) The SARS-coronavirus nsp7-nsp10 complex is a unique multimeric RNA polymerase capable of both de novo initiation and primer extension. Nucleic Acids Res 40: 1737–1747.
31. Perales C, Martin V, Domingo E (2011) Lethal mutagenesis of viruses. Curr Opin Virol 1: 419–422.
32. Stockman JJ, Bellamy R, Garner P (2006) SARS: systematic review of treatment effects. PLoS Med 3: e431. doi:10.1371/journal.pmed.0030433.
33. Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, et al. (2006) Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. Antiviral Res 71: 33–63.